Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

BACKGROUND: In the phase 3 B‐LONG study (NCT01027364), prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) every 7 to >14 days was associated with low annualized bleed rates (ABRs) in males aged ≥12 years with severe hemophilia B. The long‐term safety and efficacy of rFIXFc prophyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Amy D., Pasi, K. John, Ozelo, Margareth C., Kulkarni, Roshni, Barnowski, Christopher, Winding, Bent, Szamosi, Johan, Lethagen, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles: Haemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332734/
https://www.ncbi.nlm.nih.gov/pubmed/30656283
http://dx.doi.org/10.1002/rth2.12163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332734/
https://www.ncbi.nlm.nih.gov/pubmed/30656283
http://dx.doi.org/10.1002/rth2.12163

Ejemplares similares